Sign in
CompletedPhase 3

Cannabidiol for Fibromyalgia (The CANNFIB Trial)

Key facts

Who runs it
Marius Henriksen
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
200 people enrolled
Started
1 Mar 2021
Ended
14 Feb 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cannabidiol
  • Placebo
Record updated
25 March 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (25)Hide the full registry criteria

Who can take part

  • Informed consent obtained
  • Clinical diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) 1990 criteria
  • Average pain intensity ≥ 4 on a Numeric Rating Scale
  • No use of medical cannabis (THC/CBD) within the last six months
  • Proficiency in spoken Danish language and able to read and write in Danish

Who cannot take part

  • Pregnancy or insufficient anti-conception therapy for fertile female participants
  • Surgery scheduled for the trial period or within 3 months prior to enrollment
  • Diagnosis of Rheumatoid Arthritis or other inflammatory diseases
  • Diagnosis of other serious chronic diseases
  • History of or current diagnosis of cancer
  • History of or current epilepsy and seizures
  • History of or major depressive disorder
  • History of a suicide attempt or any suicidal behavior
  • History of severe psychiatric disorders
  • History of or current cannabis abuse
  • History of or current drug abuse
  • History of or current alcohol abuse
  • Severe personality disorder
  • Allergic reactions to the active ingredients in cannabidiol
  • On-going participation in other medical trials for pain management of fibromyalgia
  • Impaired liver and kidney function
  • Planning pregnancy or insufficient anti-conception use in fertile female partners of male participants
  • Breast feeding
  • A mental state that may impede compliance with the program
  • Current use of opioids, opioid antagonists (LDN) or similar strong analgesics

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Fibromyalgia is serious chronic pain condition which is often accompanied by sleep disturbances, fatigue and disability and reduced quality of life. There is no cure and treatments are based on reliving symptoms and maintaining function. The currently available medical treatments are not helping many patients, and many get side-effects. Medical cannabis is sought after among patients and many use this medication un-licenced, although it is not properly documented if it works or is safe. Therefore, it is necessary to investigate the effects and safety of medical cannabis in a properly designed randomized trial. The aim of the study is to investigate if cannabidiol (CBD) can improve pain, sleep, function and quality of life in patients with fibromyalgia. The study will include 200 patients, who will receive either cannabidiol or placebo over a period of 24 weeks. Participants will be closely looked after for improvements in their condition and for potential side-effects to ensure safety.

The 2 groups in the trial

  • CannabidiolTreatment being tested

    Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.

  • PlaceboPlacebo, for comparison

    Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial
Publications
Record updated
25 March 2024